-
Analysed clinical and market potential for entry into the non-small-cell lung cancer (NSCLC) market
-
Evaluated unmet needs to identify potential entry points
-
Conducted a deep-dive study of key assets and key players
CLIENT CHALLENGES
- Understanding and assessing the NSCLC market, which has numerous assets
- Undertaking a competitive assessment of pipeline drugs to identify potential drugs
- Understanding regulatory approvals, reimbursement and market access in the NSCLC market
- Evaluating unmet needs, drivers and barriers to entering the oncology market
OUR APPROACH
- Competitive landscape:
- Understanding the current standard of care (SoC) and epidemiology of NSCLC
- Understanding available diagnostic tests and associated treatments
- Mapping different assets in the NSCLC pipeline against line of therapy (LoT) and target
- Benchmarking assets
- Evaluating the safety and efficacy of approved drugs to understand benchmarking in different patient segments
- Competitive assessment of pipeline drugs to identify potential drugs
VALUE DELIVERED
- Helped the client’s team understand the landscape of the NSCLC market, considering both approved and ongoing trials
- Advised on viability of entering the NSCLC market using different parameters
- Mapping different PD-1 combination drugs against patient segments and frequently used PD-1 drugs
- Understanding approved PD-1 combination drugs and relative efficacy
Thank you for sharing your details
Your file will start downloading automatically
If it does not download within 1 minute,
Share this on
